August 29, 2014 5:15 PM ET

Biotechnology

Company Overview of BIND Therapeutics, Inc.

Company Overview

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accur...

325 Vassar Street

Cambridge, MA 02139

United States

Founded in 2006

59 Employees

Phone:

617-491-3400

Key Executives for BIND Therapeutics, Inc.

Chief Executive Officer
Age: 62
Total Annual Compensation: $395.0K
Chief Technology Officer
Age: 48
Total Annual Compensation: $301.3K
Advisor
Age: 56
Total Annual Compensation: $247.9K
Compensation as of Fiscal Year 2013.

BIND Therapeutics, Inc. Key Developments

BIND Therapeutics, Inc. Announces Presentation of Phase 2 Clinical Data on Bind-014 at 26th EORTC-NCI-AACR Symposium

BIND Therapeutics, Inc. announced that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel in tumors which translated to marked improvements in antitumor activity. In a Phase 1 study, BIND-014 was well tolerated and showed initial indications of anti-tumor activity. BIND-014 is currently in two Phase 2 trials for the treatment of non-small cell lung cancer and metastatic castrate resistant prostate cancer.

BIND Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

BIND Therapeutics, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $2,459,000, loss from operations of $8,216,000, net loss attributable to common stockholders of $8,444,000 or $0.51 per basic and diluted share compared to the revenue of $2,777,000, loss from operations of $5,632,000, net loss attributable to common stockholders of $7,331,000 or $3.32 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $4,024,000, loss from operations of $16,735,000, net loss attributable to common stockholders of $16,766,000 or $1.02 per basic and diluted share compared to the revenue of $4,265,000, loss from operations of $11,768,000, net loss attributable to common stockholders of $14,957,000 or $6.83 per basic and diluted share for the same period a year ago.

BIND Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 10:55 AM

BIND Therapeutics, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 10:55 AM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Scott L. Minick, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Cancer Advances, Inc. United States
BioParadox Inc. United States
HydraDx, Inc. United States
Diagnostic USA, Inc. United States
CureDM, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIND Therapeutics, Inc., please visit bindtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.